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ORIGINAL ARTICLE
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Aim: To study the role of gene promoter hypermethylation of the putative tumour suppressor genes involved in
the death-associated protein (DAP) kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple
myeloma (MM).
Method: DNAs from 55 primary MM marrow samples and myeloma cell lines were analysed for aberrant
promoter methylation of DAP kinase, p14 and Apaf-1 genes by methylation-specific polymerase chain
reaction (MSP).
Result: In the methylated positive control, the sensitivity of M-MSP for DAP kinase was 161023. Aberrant
hypermethylation of DAP kinase was found in 29/55 (52.7%) primary MM samples, whereas
hypermethylation of p14 or Apaf-1 was undetectable in any of the samples tested. 5-Azacytidine treatment
of two myeloma cell lines, WL2 and HS-Sultan, led to de-methylation and re-expression of DAP kinase,
thereby confirming gene silencing associated with promoter hypermethylation. Hypermethylation of DAP
kinase did not correlate with age, sex, paraprotein subtype or Durie–Salmon stage, but negatively affected
the overall survival.
Conclusion: Of the putative tumour suppressor genes in the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis
pathway, only DAP kinase is frequently methylated in MM, which is associated with gene silencing and might
be of prognostic significance. p14 and Apaf-1 were not methylated in MM.
M
ultiple myeloma (MM) is a disease with a low
proliferative rate. Plasma cells actively synthesising
DNA are typically ,1%, and increase only in advanced
disease.1 2 However, neoplastic plasma cells are protected from
apoptosis by interacting with the marrow microenvironment.1 2
Death-associated protein (DAP) kinase is a proapoptotic
calcium/calmodulin-regulated serine/threonine kinase with a
multidomain structure. It participates in a wide array of
apoptotic mechanisms initiated by interferon-a, tumour necro-
sis factor-a, activated Fas and detachment from the extra-
cellular matrix.3 DAP kinase counteracts oncogene-induced
transformation by activating p53 in a p19ARF-dependent
manner, thereby providing an intrinsic p53-dependent apopto-
tic checkpoint that is turned on by oncogenes at the initial
stages of transformation.3
p14ARF is one of the two genes encoded by the INK4A/ARF
locus at chromosome 9p21.4 Alternative first exons 1a and 1b,
under the control of different promoters, specify the 59 ends of
p16INK4A and p14ARF, respectively. These alternative exons are
spliced to the same splice acceptor site in exon 2, leading to
translation in alternative reading frames. p14 physically
associates with HDM2, which possesses E3 ubiquitin ligase
activity. HDM2 is a negative regulator of p53, mediating its
degradation in the proteosome. p14ARF binding to HMD2 leads
to inhibition of the E3 ubiquitin ligase activity, and localisation
of HDM2 to the nucleus, precluding its interaction with p53.4
Therefore, by stabilising p53, p14ARF acts as a tumour
suppressor.
In normal cells, aberrant activation of a cellular oncogene
may trigger an intrinsic tumour suppression mechanism,
leading to apoptosis and thus eradication of the transformed
cell.5 The DAP kinase/p14/HDM2/p53 pathway is one such
mechanism, leading to the downstream activation of Apaf-1
and formation of the apoptosome.6 In MM, p53 is functional in
the majority of cases, and mutation or deletion is rarely
demonstrated.7 8 Therefore, other tumour suppressor compo-
nents of this pathway may be potentially affected in the
pathogenesis of MM, in which oncogene activation is a
frequent event.1 2
DNA methylation, catalysed by DNA methyltransferase,
involves the addition of a methyl group to the carbon 5
position of the cytosine ring in the CpG dinucleotide, converting
it to methylcytosine.9 10 In many cancers, the CpG islands of
selected genes are aberrantly methylated (hypermethylated),
resulting in transcriptional repression. This may serve as an
alternative mechanism of gene inactivation.
We have demonstrated frequent epigenetic dysregulation of
cell cycle control and Jak/STAT signalling in MM.11–14 However,
as study of isolated genes or random assortment of genes
precludes interpretation of the role of hypermethylation of
putative tumour suppressor genes in a specific pathway, we
investigated the role of aberrant gene promoter hypermethyla-
tion in disrupting the DAP kinase/p14/HDM2/p53/Apaf-1 path-
way in MM. p53 was not investigated, as it does not harbour a
CpG island in the promoter region (accession number: J04238).
MATERIALS AND METHODS
Patients, diagnosis and treatment
A total of 34 male and 21 female patients with MM, with a
median age of 57 (25–87) years, were studied. The diagnosis of
MM was based on standard criteria.15 Complete staging
examination included bone marrow examination, skeletal
survey, serum and urine protein electrophoresis, and serum
immunoglobulin (IgG, IgA and IgM) levels. Monoclonal
Abbreviations: 5-AC, 5-azacytidine; DAP, death-associated protein;
HSCT, haematopoietic stem cell transplantation; MM, multiple myeloma;
MSP, methylation-specific polymerase chain reaction; OS, overall survival
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proteins were identified by electrophoresis, immunoelectro-
phoresis and immunofixation. There were 6 (10.9%) patients
with Durie–Salmon stage I, 14 (25.5%) with stage II and 35
(63.6%) with stage III. Patients with stage I or asymptomatic
disease did not receive chemotherapy until disease progression.
Patients below 65 years of age were induced with three to six
courses of vincristine, adriamycin and dexamethasone for
initial myeloma cytoreduction. Those with a human leucocyte
antigen-identical donor and below 50 years of age received
myeloablative allogeneic haematopoietic stem cell transplanta-
tion (HSCT; n = 8), and those between 50 and 65 years of age
(n = 10) received non-myeloablative HSCT. Patients without a
suitable donor received autologous HSCT up to the age of
65 years (n = 11). Patients .65 years of age were given
melphalan and prednisolone until they reached maximal
response or the plateau phase. Patients progressing from the
plateau phase received melphalan, cyclophosphamide, thalido-
mide, or vincristine, adriamycin and dexamethasone. Patients
with local symptoms due to disease received local radiotherapy.
The study was approved by the institutional review board of
Queen Mary Hospital (Hong Kong, Hong Kong) and informed
consent obtained.
Methylation-specific polymerase chain reaction
DNA was extracted from 55 myeloma marrow samples at
diagnosis and from myeloma cell lines (WL2 and HS-Sultan) by
the standard method. Methylation-specific polymerase chain
reaction (MSP) for aberrant gene promoter methylation was
performed as described previously.16 17 Treatment of DNA with
bisulphite for conversion of unmethylated cytosine to uracil
(but not affecting methylated cytosine) was performed with a
commercially available kit (CpGenome DNA modification kit,
Intergen, New York, New York, USA). The genes p14, DAP kinase
and Apaf-1 were tested. Primers for the methylated (M-MSP)
and unmethylated (U-MSP) promoters are shown in table 1.18 19
DNA from 19 normal bone marrow donors was used as negative
control, while methylated control DNA (CpGenome Universal
Methylated DNA, Intergen) was used as positive control in all
experiments. MSP was performed in a thermal cycler (9700,
ABI Biosystems, Foster City, California, USA) with the
following cycling conditions: 95 C˚ for 4 min, 35 cycles of 95 C˚
for 45 s, specific annealing temperature for 30 s, 72 C˚ for 30 s
and a final extension of 10 min at 72 C˚. The MSP mixture
contained 50 ng of bisulphite-treated DNA, 0.2 mM dNTPs,
2 mM MgCl2, 10 pmol of each primer, 16PCR buffer and 2.5 U
of AmpliTaq Gold DNA Polymerase (ABI Biosystems) in a final
volume of 50 ml. In all, 10 ml of PCR products were loaded onto
6% non-denaturing polyacrylamide gels, electrophoresed and
visualised under ultraviolet light after staining with ethidium
bromide.
Sensitivity of MSP
One microgram of DNA of the methylated positive control
(Intergen) was diluted serially (10-fold) in normal marrow
DNA, modified by bisulphite and then amplified by MSP.
5-Azacytidine treatment of the WL2 and HS-Sultan cell
l ines
The human myeloma cell lines WL2 and HS-Sultan were
cultured in Rosewell Park Memorial Institute medium supple-
mented with 10% fetal calf serum. For treatment with 5-
azacytidine (5-AC), cells from myeloma cell lines, WL2 (kindly
donated by Dr Andrew Zannettino, Myeloma and Mesenchymal
Research Laboratory, Division of Haematology, Institute of
Medical and Veterinary Science, Adelaide, Australia) and HS-
Sultan (purchased from ATCC), were seeded in six-well plates
at a density of 106 cells/ml, and cultured with 5 and 0.5 mM of
5-AC (Sigma, St Louis, Missouri, USA) for 5 days, with fresh
medium containing 5-AC replenished every 2 days. Cells on
days 0 and 5 of 5-AC treatment were harvested.
Reverse transcription-PCR
One microgram of total cellular RNA was reverse transcribed
with M-MLV reverse transcriptase (Life Technologies, Rockville,
Maryland, USA). cDNA was amplified by PCR with DAP kinase-
specific primers (forward: 59-GATAGAAATGTCCCCAAA-
CCTCG-39 and reverse: 59-TCTTCTTGGATCCTTGACCAGAA-39,
which spanned nucleotides 781–1124, Genbank accession
number: X76104). RNA that was not reverse transcribed served
as control. Reverse transcription-PCR for glyceraldehyde 3-
phosphate dehydrogenase (forward: 59-GAAGGTGAAGGTC-
GGAGTC-39 and reverse: 59-GAAGATGGTGATGGGATTC-39)
was performed to confirm RNA integrity. PCR conditions for
DAP kinase were 35 cycles of 95 C˚ for 30 s, 58 C˚ for 60 s and
72 C˚ for 60 s, and those for glyceraldehyde 3-phosphate
dehydrogenase 30 cycles of 95 C˚ for 30 s, 60 C˚ for 30 s and
Table 1 Methylation-specific polymerase chain reaction: primer sequences and reaction
conditions
Gene Forward primer (59–39) Reverse primer (59–39) Tm/cycles Reference
DAP kinase
M-MSP GGATAGTCGGAT
CGAGTTAACGTC
CCCTCCCAAA
CGCCGA
63 C˚/35 Chan et al19
(2002)
U-MSP GGAGGATAGTTG
GATTGAGTTAATGTT
CAAATCCCTCCC
AAACACCAA
P14
M-MSP GTGTTAAAG
GGCGGCGTAGC
AAAACCCTC
ACTCGCGACGA
65 C˚/35 Esteller et al18
(2000)
U-MSP TTTTTGGTGT
TAAAGGGTGGTGTAGT
CACAAAAAC
CCTCACTCACAACAA
Apaf-1
M-MSP* TATTGCGATATTGTT
TTAAATTCGA
GAAACGTAACTAAA
CCTCAAAAACG
64 C˚/35 Genebank
U-MSP** TATTGTGATATTGTT
TTAAATTTGA
CAAAACATAACTAA
ACCTCAAAAACAC
AB070 829
DAP, death-associated protein; M-MSP, methylation-specific polymerase chain reaction for the methylated allele; U-
MSP, MSP for the unmethylated allele; Tm, annealing temperature.
Primers for Apaf-1: M-MSP*, nucleotides 785–809; U-MSP**, nucleotides 938–963 in Genbank accession number:
AB070829.
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72 C˚ for 30 s. PCR products were electrophoresed on 6% non-
denaturing polyacrylamide gels, stained with ethidium bromide
and visualised under UV illumination. The identity of the PCR
products was confirmed by DNA sequencing.
Statistical analysis
Association between DAP kinase hypermethylation and other
clinical parameters (age, sex, Durie–Salmon stage, paraprotein
subtypes) was studied by the x2 test (for categorical variables)
or Student’s t test (for continuous variables). Overall survival
(OS) was measured from the date of diagnosis to the date of
last follow-up or death. Survival was estimated by the Kaplan–
Meier method and compared by the log-rank test. All p values
were two-sided.
RESULTS
Methylation-specific polymerase chain reaction
None of the 19 normal control marrows showed aberrant
methylation of p14, DAP kinase and Apaf-1 (fig 1B, 2A,B). The
positive and negative controls showed the expected MSP results
(normal DNA, U-MSP positive/M-MSP negative; methylated
DNA: U-MSP negative/M-MSP positive). Sequencing of the
MSP products showed the expected nucleotide changes after
bisulphite treatment (fig 1A, 2A,B). For the primary MM
samples, DAP kinase was methylated in 29 cases (52.7%; fig 1C),
whereas p14 and Apaf-1 were not methylated in any of the
samples (fig 2A,B).
Sensitivity of DAP kinase M-MSP
For the positive control, the sensitivity of M-MSP was 161023
for DAP kinase (fig 1D).
5-AC treatment of WL2 myeloma cell line
DAP kinase was completely methylated and consequently not
expressed in WL2 and HS-Sultan also. 5-AC treatment of both
cell lines resulted in partial demethylation of DAP kinase, as
evidenced by positive U-MSP amplification and gene expression
on day 5 (fig 3).
Statistical analysis
DAP kinase hypermethylation was not associated with age
(p = 0.16), sex (p = 0.59), Durie–Salmon stage (p = 0.76) and
paraprotein subtypes (p = 0.37; table 2). However, DAP kinase
hypermethylation was significantly associated with an inferior
median OS (methylated 34 months vs unmethylated
80 months, p = 0.013; fig 4).
DISCUSSION
We showed that DAP kinase was frequently methylated in MM
samples, whereas p14 and Apaf-1 were not. Therefore, abroga-
Figure 1 Methylation-specific polymerase chain reaction (MSP) of death-associated protein (DAP) kinase. (A) Sequence analysis of the methylated MSP
(M-MSP) product showed the expected changes after bisulphite treatment. Wild-type (WT) cytosine (C) residues that remained unchanged in methylated
CpG were coloured blue and underlined, while those that were changed to thymidine (T) were coloured red and underlined. (B) Unmethylated MSP (U-MSP)
and M-MSP showing the expected results, with all 19 normal controls (N1–N19) amplifying in U-MSP but not in M-MSP, and the methylated positive control
(P) amplifying only in M-MSP but not in U-MSP. MW, molecular weight marker; B, reagent blank; P, positive control of methylated DNA; N1–N19, normal
marrow DNA. (C) For the MM samples, samples 2 and 3 (S2, S3) showed DAP kinase hypermethylation. B, reagent blank; P, positive control of methylated
DNA; S1–4, MM marrow DNA. (D) M-MSP of the serially diluted methylated positive control DNA, showing a sensitivity of 1 in 103. BM, bone marrow;
MM, multiple myeloma.
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tion of the putative tumour suppressor genes involved in the
DAP kinase-related apoptotic pathway in some cases might
collaborate with other antiapoptotic signals from the micro-
environment to enhance the survival of neoplastic plasma
cells.1 2 Moreover, as concomitant abrogation of multiple
tumour suppressors of this apoptosis pathway does not confer
additional survival benefit, our findings suggested that hyper-
methylation of tumour suppressor components of this apopto-
sis pathway appears to be mutually exclusive.
Despite the sensitivity of DAP kinase MSP being only 1 in 103,
the methylation status of the neoplastic plasma cells should
preferably be studied by CD138-sorted plasma cells.
Figure 2 (A) Methylation-specific polymerase chain reaction (MSP) of p14 showing the sequence of methylated positive control (upper panel: wild-type
(WT) cytosine (C) residues that remained unchanged in methylated CpG are coloured blue and underlined, while those that were changed to thymidine (T)
are coloured red and underlined), absence of p14 hypermethylation in normal control DNA (middle panel: presence of unmethylated MSP (U-MSP) but
absence of methylated MSP (M-MSP) amplification in normal control DNA) and primary myeloma marrow samples (lower panel: presence of U-MSP but
absence of M-MSP amplification in normal control DNA). (B) MSP of Apaf-1 showing the sequence of methylated positive control (upper panel: WT cytosine
(C) residues that remained unchanged in methylated CpG are coloured blue and underlined, while those that were changed to thymidine (T) are coloured
red and underlined), absence of p14 hypermethylation in normal control DNA (middle panel: presence of U-MSP but absence of M-MSP amplification in
normal control DNA) and primary myeloma marrow samples (lower panel: presence of U-MSP but absence of M-MSP amplification in normal control
DNA). B, reagent blank; M, M-MSP; MM, multiple myeloma; MW, molecular weight; N1–N8, normal marrow DNA; S1–S4, myeloma marrow samples; U,
U-MSP
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In the myeloma cell lines WL2 and HS-Sultan, DAP kinase
hypermethylation was associated with the absence of tran-
script, which was re-expressed after 5-AC treatment. As 5-AC is
a DNA methyltransferase inhibitor, and thus a demethylating
agent, re-expression of the transcript after 5-AC treatment
confirmed gene silencing-associated gene promoter hyper-
methylation.
In this study, DAP kinase hypermethylation was associated
with an inferior OS but not with Durie–Salmon stage. The latter
could be due to the retrospective nature of the study, the small
number of patients and the heterogeneity of treatment. For
instance, 29 (52.7%) of our patients have undergone bone
marrow transplantation. Therefore, the prognostic value of DAP
kinase methylation needs verification in future prospective
clinical trials with a larger number of patients receiving
uniform treatment.
The oncogenic role of DAP kinase/p14/Apaf-1 has been
demonstrated in previous studies. DAP kinase expression was
shown to suppress the metastatic potential of tumour cells in
animal models.21 Modest frequency of DAP kinase hypermethy-
lation (10–20%) has been identified in lung, colon, and head
and neck cancers.22 In contrast, frequent (66–72%) DAP kinase
hypermethylation was demonstrated in B-cell lymphoma and
MM.23 24 Moreover, DAP kinase has been shown to be
methylated in patients with monoclonal gammopathy of
undetermined significance at a frequency comparable with
that with MM.25 p14 hypermethylation was found in 10–30% of
renal, gastric and colorectal cancers.22 In haematological
malignancies, p14 hypermethylation was present in 40% of
chronic myeloid leukaemia cases in acceleration,26 but in only
8% of acute lymphoblastic leukaemia cases,27 and in none of the
therapy-related myelodysplastic syndrome/acute myeloid leu-
kaemia cases.28 In MM, one previous study showed p14
hypermethylation in 9% of the patients.29 The infrequent p14
hypermethylation was consistent with results from another
study, which showed p14 expression in MM.30 Furthermore, as
the p14/p16 locus was not found to be deleted in MM,31 p14 does
not appear to be targeted in MM. Finally, while hypermethyla-
tion of Apaf-1 has been detected in melanoma,32 and recently in
leukaemia,26 this is the first report demonstrating the absence
of Apaf-1 hypermethylation in MM.
In conclusion, of the putative tumour suppressor genes in the
DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway, only
DAP kinase is frequently methylated in MM, which is associated
with gene silencing. p14 and Apaf-1 were not methylated in
Figure 3 5-Azacytidine (5-AC) treatment of WL2 and HS-Sultan. Death-
associated protein (DAP) kinase was unmethylated in the normal marrow
control (NC), which was associated with expression of DAP kinase
transcript. On day 0 (D 0), DAP kinase was completely methylated in WL2
and HS-Sultan, with a corresponding absence of DAP kinase transcript. At
5 days after treatment (D 5), partial de-methylation of DAP kinase
occurred, leading to positive amplification in unmethylated methyl-specific
polymerase chain reaction (U-MSP), and expression of the DAP kinase
transcript. B, blank; MW, molecular weight marker; NC, normal marrow
control; NRT, non-reagent control; PC, positive control of methylated DNA.
Table 2 Correlation of death-associated protein kinase
hypermethylation and patient characteristics
DAP
kinase Methylated Unmethylated p Value
Number 29 26
Median
age
60.0 54.5 0.16
Sex 0.59
Male 19 15
Female 10 11
Ig subtype 0.37
IgG 19 15
IgA 7 4
IgD 0 1
Light chain 3 6
Durie–Salmon
stage
0.76
(II 11 9
III 18 17
DAP, death-associated protein.
Figure 4 Overall survival (OS) of patients with and without death-
associated protein (DAP) kinase hypermethylation. DAP kinase
hypermethylation was associated with an inferior OS.
Take-home messages
N Death-associated protein (DAP) kinase, a tumour sup-
pressor gene regulating p53-mediated apoptosis, is
potentially important in myeloma pathogenesis because
of its frequent methylation.
N DAP kinase hypermethylation might be of prognostic
significance.
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MM. The high sensitivity of DAP kinase MSP might be a useful
marker for monitoring of minimal residual disease.
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